Pharmacokinetic effects of conversion to a new formulation of cyclosporin A in rheumatoid arthritis patients

Rheumatology International

Volumn 17, Issue 5, 1998, Pages 197-202

  Marchesoni, A ^a   Fantini, F ^a   Battafarano, N ^a   Zeni, S ^a   Ruiu, G ^b   Padula, A ^b   Taglione, E ^b   Pasero, G ^b   Leoni, L ^c  

^a Hospital G Pini   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Cyclosporin A; Pharmacokinetics; Rheumatoid arthritis; Sandimmun Neoral

Indexed keywords

CYCLOSPORIN A;

ANALYTICAL PARAMETERS; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; HUMAN; MALE; MICROEMULSION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REPRODUCIBILITY; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; ARTHRITIS, RHEUMATOID; BIOLOGICAL AVAILABILITY; BLOOD PRESSURE; CHEMISTRY, PHARMACEUTICAL; CREATININE; CROSS-OVER STUDIES; CYCLOSPORINE; DATA INTERPRETATION, STATISTICAL; DIASTOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL DISEASES; GINGIVAL HYPERPLASIA; HEADACHE; HEMOGLOBINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JOINTS; KIDNEY FUNCTION TESTS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; SYSTOLE; TIME FACTORS; TREMOR; URIC ACID;

EID: 0031913235     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002960050034     Document Type: Article

References (14)

1. Kahan BD (1989) Cyclosporine. N Engl J Med 321: 1725-1738
2. Lemaire M, Fahr A, Maurer G (1990) Pharmacokinetics of cyclosporine: inter- and intraindividual variations and metabolic pathways. Transplant Proc 22: 1110-1112
3. Grevel J (1992) Optimisation of immunosuppressive therapy using pharmacokinetic principles. Clin Pharmacokinet 23: 380-390
4. Drewe J, Meir R, Vonderscher J, Kiss D, Posanski U, Kissel T, Gyr K (1992) Enhancement of the oral absorption of cyclosporin in man. Br J Clin Pharmacol 34: 60-64
5. Kovarik JM, Mueller EA, Johnston A, Hitzenberger G, Kutz K (1993) Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporin formulation. Pharmacotherapy 13: 613-617
6. Mueller EA, Kovarik JM, van Bree JB, Lison AE, Kuts K (1994) Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients. A concentration-controlled comparison with the commercial formulation. Transplantation 57: 1178-1182
7. Winkler M, Ringe B, Schneider K, Maibücher A, Färber L, Wietholtz H, Manns M, Pichlmayr R (1994) Enhanced bioavailability of cyclosporine using a new oral formulation (Sandimmun optoral) in a liver-grafted patient with severe cholestasis (letter). Transplant Int 7: 147-148
8. Van Den Borne BEE, Landewé RBM, Goei The HS, Mattie H, Breedveld FC, Dijkmans BAC (1995) Relative bioavailability of a new oral form of cyclosporin A in patients with rheumatoid arthritis. Br J Clin Pharmacol 39: 172-175
9. Panayi GS (1993) The immunopathogenesis of RA. Br J Rheumatol 32 [Suppl 1]: 4-14
10. Wells G, Tugwell P (1993) Cyclosporin A in rheumatoid arthritis: overview of efficacy. Br J Rheumatol 32 [Suppl 1]: 51-56
11. Pasero G, Priolo F, Marubini E, Fantini F, Ferraccioli G, Magaro M, Marcolongo R, Oriente P, Pipitone V, Portioli I, Tirri G, Trotta F, Della Casa-Alberighi O (1996) Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 39: 1006-1015
12. Wang P, Meucci V, Simpson E, Morrison M, Lunetta S, Zaja M, Boecky R (1990) A monoclonal antibody fluorescent polarisation immunoassay for cyclosporine. Transplant Proc 22: 1186-1188
13. Grevel J, Welsh MS, Kahan BD (1989) Cyclosporine monitoring in renal transplantation: area under the curve monitoring is superior to through-level monitoring. Drug Monit 11: 246-248
14. Feutren G (1992) The optimal use of cyclosporin A in autoimmune diseases. J Autoimmun 5 [Suppl A]: 183-185